Native methylation sequencing for analysis of neurodegenerative conditions

In this presentation, Chad Pollard, CEO of Renew Biotechnologies, explores how the native sequencing capabilities of Oxford Nanopore technology are revolutionizing the research and detection of neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and ALS. By developing NeuroLens, a novel cell-free DNA technology, Chad explains how the company utilizes methylation signatures to track cell death in the brain through simple blood tests. This approach moves beyond traditional diagnostic limitations, offering a more precise, scalable method for identifying disease-specific cell-of-origin signals.

View the full presentation on nanoporetech.com